IXICO Hails The Introduction of IXIQ.Ai, Its New Brain Imaging Technology
The new platform has been developed and validated in collaboration with academic and pharma partners, the company said.
IXICO said its next-generation brain imaging technology that is more sensitive, accurate and flexible than the current platform will be available for clinical trials from next month (March).
Used for virtual brain segmentation and based on artificial or convolutional neural networks, IXIQ.Ai has been developed and validated in collaboration with academic and pharma partners, the company said.
It has optimised its approach to detect smaller treatment effects as it assesses the impact on the brain of the active drugs used in human studies.
IXICO said the accuracy of the new approach “enables patient-level decision making”, and it added that the tech can be customised to the clinical trial’s needs.
Chief scientific officer, Dr Robin Wolz, said IXIQ.Ai has been developed over more than a decade and uses artificial intelligence (AI) tools such as deep learning,
In doing so it has increased the number of datasets it has at its disposal to enable accurate and automated measurement of complex brain structures to better understand central nervous system diseases.
“Initial applications are focused on areas with a high unmet need, and we are already planning application of the platform across a wider range of indications to enable the provision of insights previously not possible,” Wolz said.
Originally published on:Proactive